Anthony S. Marucci
Founder, President, Chief Executive Officer and Director
Mr. Marucci is a Founder of Celldex and serves as the Company’s President and Chief Executive Officer and as a member of the Board of Directors. Prior to his appointment as President and CEO in 2008, Mr. Marucci served as Vice President, Chief Financial Officer, Treasurer and Secretary of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci is also responsible for the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions since December 1998. He is a member of the Board of Trustees of BioNJ and also served as its Treasurer through 2010. Mr. Marucci received a B.S. in Accounting from Kean University, an MBA from Columbia University and an Executive Master of Healthcare Leadership (EMHL) from Brown University.
Avery W. (Chip) Catlin
Senior Vice President, Chief Financial Officer and Secretary
Mr. Catlin joined Celldex in January 2000 as Senior Vice President and Chief Financial Officer. He also serves as Secretary. Prior to joining Celldex, he served as Vice President, Operations and Finance, and Chief Financial Officer of Endogen, Inc., a public life science research products company, from 1996 to 1999. From 1992 to 1996, he held various financial positions at Repligen Corporation, a public biopharmaceutical company, serving the last two years as Chief Financial Officer. Earlier in his career, he held the position of Chief Financial Officer at MediSense, Inc., a Massachusetts-based medical device company. Mr. Catlin received his B.A. degree from the University of Virginia and M.B.A. from Babson College and is a Certified Public Accountant.
Senior Vice President, Chief Product Development Officer
Elizabeth Crowley is Senior Vice President, Chief Product Development Officer of Celldex. Ms. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations, responsible for strategic and operational development activities of the oncology and oncology supportive care portfolio, regulatory affairs, clinical operations and data management. Ms. Crowley started her career at Bayer Corporation in 1992, holding various positions providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management, assuring the highest standards for program execution. Ms. Crowley received her BS in Chemistry with a concentration in Business from Boston College.
Thomas Davis, M.D.
Executive Vice President and Chief Medical Officer
Dr. Davis is Executive Vice President and Chief Medical Officer of Celldex. Prior to this appointment in 2014, he was Senior Vice President of Clinical Development and Chief Medical Officer of Celldex. Formerly he was Chief Medical Officer at GenVec and Senior Director of Clinical Science at Medarex. He has supervised clinical efforts in adult hematologic malignancies and marrow transplantation and therapeutic antibodies and vaccines at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and worked with Dr. Ron Levy on the development of rituximab and idiotype vaccines at Stanford University. Dr. Davis received his B.A. in Biophysics from Johns Hopkins, M.S. in Physiology and M.D. from Georgetown University, and Oncology training at Stanford University.
Tibor Keler, Ph.D.
Founder, Executive Vice President and Chief Scientific Officer
Dr. Keler is a Founder of Celldex and serves as the Company’s Executive Vice President and Chief Scientific Officer. Prior to this appointment in 2014, he was Senior Vice President of Research and Discovery at Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). Previously, Dr. Keler was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the preclinical development of a number of Medarex clinical product candidates. In addition, Dr. Keler was responsible for the development of Celldex's core technology and related products. Dr. Keler received his Ph.D. in Microbiology from the University of Pennsylvania.
Theresa LaVallee, Ph.D.
Senior Vice President, Regulatory and Precision Medicine
Dr. LaVallee joined Celldex in November 2016 as Senior Vice President, Regulatory and Precision Medicine. Dr. LaVallee most recently served as Senior Vice President, Translational Medicine and Product Development at Kolltan Pharmaceuticals, and was responsible for developing and executing the research and development strategy. She established and expanded the Company’s translational medicine, project management and development capabilities to transition Kolltan from a preclinical to clinical stage company, including leading the regulatory strategy behind these programs. Prior to Kolltan, Dr. LaVallee held increasingly senior level roles at MedImmune/AstraZeneca and EntreMed. Dr. LaVallee started her career as a research scientist and has published extensively on her work throughout her career. She received her Ph.D. in Microbiology and Molecular Genetics from the University of California, Los Angeles.
Ronald A. Pepin, Ph.D.
Senior Vice President and Chief Business Officer
Dr. Pepin joined Celldex in July 2011 as Senior Vice President and Chief Business Officer. He previously served as Vice President at Shire Pharmaceuticals. From 2000 – 2009, as Senior Vice President, Business Development at Medarex, Inc., he was instrumental in establishing more than forty collaborations with global biopharmaceutical companies. Earlier in his career, he served as Executive Director of External Science and Technology at Bristol-Myers Squibb. Dr. Pepin received his B.A. from Tufts University and his Ph.D. in Genetics from Georgetown University.
Richard Wright, Ph.D.
Senior Vice President and Chief Commercial Officer
Dr. Wright is Senior Vice President and Chief Commercial Officer of Celldex. He joined Celldex in 2012 as Vice President of Commercial Operations. Prior to Celldex, Dr. Wright was Managing Director at Navigant Consulting, where he led a Life Sciences practice focused on commercial strategy for oncology, immunology and rare disease therapies. Previously, Dr. Wright was at Bristol-Myers Squibb, where he held senior leadership roles including Senior Vice President of the U.S. Immunology Business and Vice President and Global Commercial Lead for the Immunology Franchise. At Bristol-Myers Squibb, he was responsible for CTLA4-Ig immunotherapies including the blockbuster drug ORENCIA® and the orphan drug NULOJIX®. In these roles he was charged with setting overall business strategy, commercializing the Company’s broad immunology franchise and managing the U.S. marketing and sales organizations. Dr. Wright began his career at Novartis Pharmaceuticals (Sandoz), where he led research aimed at discovering novel inhibitors of cell migration and metastasis, inhibition of tumor-induced angiogenesis and induction of immune tolerance. At Novartis, he later held several roles in new product commercialization, marketing and salesforce leadership in its Transplant and Immunology Business Unit and was responsible for NEORAL®, SIMULECT®, CERTICAN® and MYFORTIC®. Dr. Wright received his B.S. in Biological Sciences from Rutgers University and his M.S. and Ph.D. in Microbiology and Molecular Genetics from The University of Medicine and Dentistry of New Jersey (Rutgers University). He received an M.B.A. in Marketing and Finance from Columbia University.